AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 249 filers reported holding AMICUS THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $34,436,269 | -2.6% | 2,831,930 | +0.6% | 0.01% | 0.0% |
| Q2 2023 | $35,373,005 | +17.4% | 2,816,322 | +3.7% | 0.01% | +16.7% |
| Q1 2023 | $30,129,689 | -8.5% | 2,716,834 | +0.7% | 0.01% | -14.3% |
| Q4 2022 | $32,937,365 | +18.4% | 2,697,573 | +1.3% | 0.01% | +16.7% |
| Q3 2022 | $27,809,000 | -3.9% | 2,663,688 | -1.1% | 0.01% | 0.0% |
| Q2 2022 | $28,934,000 | +13.6% | 2,694,101 | +0.2% | 0.01% | +50.0% |
| Q1 2022 | $25,461,000 | -21.1% | 2,688,640 | -3.8% | 0.00% | -20.0% |
| Q4 2021 | $32,283,000 | +19.4% | 2,795,037 | -1.3% | 0.01% | 0.0% |
| Q3 2021 | $27,036,000 | -5.1% | 2,831,000 | -4.2% | 0.01% | 0.0% |
| Q2 2021 | $28,489,000 | -2.6% | 2,955,285 | -0.2% | 0.01% | 0.0% |
| Q1 2021 | $29,253,000 | -60.7% | 2,960,716 | -8.2% | 0.01% | -66.7% |
| Q4 2020 | $74,486,000 | +59.6% | 3,225,905 | -2.4% | 0.02% | +50.0% |
| Q3 2020 | $46,659,000 | -11.8% | 3,304,497 | -5.8% | 0.01% | -23.1% |
| Q2 2020 | $52,928,000 | +70.1% | 3,509,747 | +4.2% | 0.01% | +44.4% |
| Q1 2020 | $31,115,000 | -4.0% | 3,367,516 | +1.2% | 0.01% | +28.6% |
| Q4 2019 | $32,424,000 | +24.1% | 3,328,849 | +2.2% | 0.01% | +16.7% |
| Q3 2019 | $26,131,000 | -21.3% | 3,258,409 | +22.5% | 0.01% | -25.0% |
| Q2 2019 | $33,192,000 | -3.3% | 2,659,611 | +5.4% | 0.01% | 0.0% |
| Q1 2019 | $34,314,000 | +46.7% | 2,523,090 | +3.3% | 0.01% | +14.3% |
| Q4 2018 | $23,398,000 | -20.9% | 2,442,390 | -0.1% | 0.01% | 0.0% |
| Q3 2018 | $29,571,000 | -20.9% | 2,445,877 | +2.1% | 0.01% | -22.2% |
| Q2 2018 | $37,401,000 | +13.5% | 2,394,490 | +9.3% | 0.01% | 0.0% |
| Q1 2018 | $32,953,000 | +16.2% | 2,191,046 | +11.1% | 0.01% | +28.6% |
| Q4 2017 | $28,369,000 | -4.8% | 1,971,488 | -0.3% | 0.01% | -12.5% |
| Q3 2017 | $29,812,000 | +70.3% | 1,976,859 | +13.7% | 0.01% | +60.0% |
| Q2 2017 | $17,502,000 | +45.6% | 1,738,010 | +3.1% | 0.01% | +66.7% |
| Q1 2017 | $12,017,000 | +49.8% | 1,685,441 | +4.4% | 0.00% | +50.0% |
| Q4 2016 | $8,021,000 | -32.3% | 1,613,842 | +0.9% | 0.00% | -50.0% |
| Q3 2016 | $11,841,000 | +51.1% | 1,600,116 | +11.5% | 0.00% | +33.3% |
| Q2 2016 | $7,839,000 | -29.6% | 1,435,680 | +9.0% | 0.00% | -25.0% |
| Q1 2016 | $11,134,000 | -11.6% | 1,317,542 | +1.5% | 0.00% | 0.0% |
| Q4 2015 | $12,595,000 | -28.7% | 1,298,508 | +2.8% | 0.00% | -33.3% |
| Q3 2015 | $17,677,000 | +411.8% | 1,263,541 | +417.6% | 0.01% | +500.0% |
| Q2 2015 | $3,454,000 | +92.2% | 244,095 | +47.8% | 0.00% | 0.0% |
| Q1 2015 | $1,797,000 | +46.9% | 165,154 | +12.3% | 0.00% | – |
| Q4 2014 | $1,223,000 | +131.6% | 147,005 | +65.8% | 0.00% | – |
| Q3 2014 | $528,000 | -51.4% | 88,658 | -72.7% | 0.00% | – |
| Q2 2014 | $1,086,000 | +30.7% | 324,924 | -19.1% | 0.00% | – |
| Q1 2014 | $831,000 | -17.1% | 401,450 | -5.9% | 0.00% | – |
| Q4 2013 | $1,003,000 | +2.5% | 426,592 | +1.0% | 0.00% | – |
| Q3 2013 | $979,000 | -1.4% | 422,234 | -1.0% | 0.00% | – |
| Q2 2013 | $993,000 | – | 426,498 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |